These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 22029645)

  • 1. Normocalcaemic normomagnesaemic tetany with tacrolimus.
    Aiyangar A; Chowdhary P; Rao K; Kiran K
    Nephrology (Carlton); 2011 Nov; 16(8):784-5. PubMed ID: 22029645
    [No Abstract]   [Full Text] [Related]  

  • 2. Generic tacrolimus in renal transplantation: trough blood concentration as a surrogate for drug exposure.
    Connor A; Prowse A; MacPhee I; Rowe PA
    Transplantation; 2012 Jun; 93(12):e45-6. PubMed ID: 23318306
    [No Abstract]   [Full Text] [Related]  

  • 3. A case of tacrolimus (FK506)-induced pancreatitis and fatality 2 years postcadaveric renal transplant.
    Ogunseinde BA; Wimmers E; Washington B; Iyob M; Cropper T; Callender CO
    Transplantation; 2003 Jul; 76(2):448. PubMed ID: 12883222
    [No Abstract]   [Full Text] [Related]  

  • 4. Acquired Glanzmann's thrombasthenia variant and immune thrombocytopenia in a renal transplant recipient receiving tacrolimus.
    Morath C; Hoffmann T; Kirchhoff EM; Sis J; Zeier M; Scharf RE; Andrassy K
    Thromb Haemost; 2005 Oct; 94(4):879-80. PubMed ID: 16270646
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeting High Calcineurin Inhibitor Levels After Acute Rejection With Less Tremor: A New Strategy.
    Alhamad T; Venkatachalam K; Daloul R; Brennan DC; Malone AF
    Transplantation; 2017 Aug; 101(8):e287-e288. PubMed ID: 28422926
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacogenetic vs. concentration-controlled optimization of tacrolimus dosing in renal allograft recipients.
    Kuypers DR
    Clin Pharmacol Ther; 2010 Nov; 88(5):595-6; author reply 597. PubMed ID: 20664539
    [No Abstract]   [Full Text] [Related]  

  • 7. Tacrolimus: a superior agent to OKT3 for treating cases of persistent rejection after intrathoracic transplantation.
    Meiser BM; Uberfuhr P; Fuchs A; Schulze C; Nollert G; Mair H; Martin S; Pfeiffer M; Reichenspurner H; Kreuzer E; Reichart B
    J Heart Lung Transplant; 1997 Aug; 16(8):795-800. PubMed ID: 9286771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunosuppressive agents in kidney transplantation].
    Nishi S
    Nihon Jinzo Gakkai Shi; 2011; 53(1):1-5. PubMed ID: 21370569
    [No Abstract]   [Full Text] [Related]  

  • 9. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial.
    Jonas S; Kling N; Bechstein WO; Blumhardt G; Lohmann R; Lobeck H; Neuhaus P
    Clin Transplant; 1995 Oct; 9(5):406-14. PubMed ID: 8541635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.
    Woodle ES; Bruce DS; Josephson M; Newell KA; Piper JB; Millis JM; Cronin D; Whitman G; Ruebe M; Thistlethwaite JR
    Clin Transplant; 1996 Aug; 10(4):323-32. PubMed ID: 8884103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tacrolimus in kidney transplantation.
    Kliem V; Brunkhorst R
    Contrib Nephrol; 1998; 124():103-16; discussion 116-25. PubMed ID: 9761977
    [No Abstract]   [Full Text] [Related]  

  • 12. Preliminary experience with FK 506 in pancreas transplant recipients.
    Stratta RJ; Taylor RJ; Castaldo P; Sindhi R; Sudan D; Frisbie K; Cushing K
    Transplant Proc; 1995 Dec; 27(6):3024. PubMed ID: 8539823
    [No Abstract]   [Full Text] [Related]  

  • 13. Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?
    van Gelder T; Hesselink DA
    Clin Pharmacol Ther; 2010 Jun; 87(6):640-1. PubMed ID: 20485320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New-onset diabetes after transplantation--should it be a factor in choosing an immunosuppressant regimen for kidney transplant recipients.
    Chadban S
    Nephrol Dial Transplant; 2008 Jun; 23(6):1816-8. PubMed ID: 18326882
    [No Abstract]   [Full Text] [Related]  

  • 15. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
    Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
    Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Importance of erythrocyte magnesium in the diagnosis and treatment of certain tetanies].
    Schirardin H; Misson C
    Sem Hop; 1967 Dec; 43(51):3252-7. PubMed ID: 4299869
    [No Abstract]   [Full Text] [Related]  

  • 17. What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus?
    Hanto DW; Chudzinski R
    Transplantation; 2009 Jan; 87(2):164-5. PubMed ID: 19155968
    [No Abstract]   [Full Text] [Related]  

  • 18. Tacrolimus (FK 506)-induced hemolytic uremic syndrome after heart transplantation.
    Walder B; Ricou B; Suter PM
    J Heart Lung Transplant; 1998 Oct; 17(10):1004-6. PubMed ID: 9811409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion from cyclosporine to tacrolimus in hepatic and renal transplantation.
    Yussim A; Shaharabani E; Mor E; Lustig S; Bar-Nathan N; Shmueli D; Sobolev V; Dorfman B; Or H; Shapira Z
    Transplant Proc; 1996 Dec; 28(6):3178-9. PubMed ID: 8962233
    [No Abstract]   [Full Text] [Related]  

  • 20. [Immunosuppression and the problems in partial liver transplantation].
    Kawasaki M; Hashikura Y; Matsunami H; Makunouchi M
    Nihon Rinsho Meneki Gakkai Kaishi; 1995 Dec; 18(6):683. PubMed ID: 8963785
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.